Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma

Nuclear Medicine Communications

Volumn 32, Issue 3, 2011, Pages 212-220

  Tamilia, Michael ^a   Al Kahtani, Nora ^a   Rochon, Louise ^a   Hier, Michael P ^a   Payne, Richard J ^a   Holcroft, Christina A ^a   Black, Martin J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

131 I therapy; low activity 131 I; remnant ablation; thyroglobulin; thyroid cancer

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; RADIOISOTOPE THERAPY; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME;

ABLATION TECHNIQUES; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIATION DOSAGE; ROC CURVE; THYROGLOBULIN; THYROID GLAND; THYROID HORMONES; THYROID NEOPLASMS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 79451471106     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328341c802     Document Type: Article

References (31)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787-803.
3. American Joint Committee on Cancer. Thyroid. In: AJCC Cancer Staging Handbook. Chapter 8. 6th edition. New York: Springer; 2002, pp. 89-98.
4. Hay I. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol 2006; 94:692-700.
5. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668-3676.
6. Hackshaw AK, Harmer C, Mallick U, Haq M, Franklyn J. 131-I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007; 92:28-38.
7. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen Joensuu H. Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. Plos One 2008; 3:e1885.
8. Ron E. Radioiodine treatmentforthyroid cancer as a riskfactorfor a second malignancy. Clinical Thyroidology 2008; 20:2-5.
9. Rosai J, Carangiu ML, Delellis RA. Tumors of the thyroid gland. In: Juan Rosai, editor. Atlas oftumorpathology. 3rd edition, fascicle 5. Washington DC: AFIP; 1992. pp. 65-121.
10. Canadian Thyroid Cancer Support Group (Thry'vors) Inc. Toronto, Ontario: Low Iodine Diet. www.thryvors.org.
11. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877-3885.
12. KimTY, Kim WB, Kim ES, Ryu JS,YeoJS, Kim SC, et al. Serumthyroglobulin levels at the time of 131-I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:1440-1445.
13. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987; 12:500-512.
14. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073MBq and 3700MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252-254.
15. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131-I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77:2574-2580.
16. Kusacic Kuna S, Samardzic T, Tesic V, Medvedec M, Kuna K, Bracic I, et al. Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate and high activities of radioiodine. Nucl Med Commun 2009; 30:263-269.
17. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, et al. Ablation of thyroid residues with 30-mCi 131-I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063-4068.
18. Barbaro D, Boni G, Menucci G. Radioiodine treatment with 30 mCi after rhTSH in thyroid cancer: effectiveness of post surgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003; 88:4100-4115.
19. Karam M, Feustel PJ, Postal ES, Cheema A, Goldfarb CR. Successful thyroid tissue ablation as defined by a negative whole body scan or an undetectable thyroglobulin: a comparative study. Nucl Med Commun 2005; 26:331-336.
20. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study of 445 patients. Thyroid 2009; 19:707-716.
21. BonnetS, Harti D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2cm: implication for radioiodine treatment. J Clin Endocrinol Metab 2009; 94:1162-1167.
22. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Med 1999; 26:1448-1452.
23. Oyen WJ, Verhagen C, Saris E, Van der Broek WJ, Pieters GF, Corsten FH. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 2000; 41:643-646.
24. Lin JD, Huang MJ, Hsu BR, Chao T, Hsueh C, Liu FH, et al. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 2002; 80:45-51.
25. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 131-I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004; 45:988-994.
26. Heemstra KA, Liu YY, Stokkelt M, Kievit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clinical Endocrinology 2007; 66:58-64.
27. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behaviour and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 289 cases. J Clin Endocrinol Metab 2004; 89:3713-3720.
28. Jury HPT, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 2009. [E-pubdoi: 10.1210/jc.2009-1624]
29. Spencer CA, Bergoglio LM, Kazarosyn M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005; 90:5566-5577.
30. Morris LF,Waxman AD, Braunstein GD. The non-impact of thyroid stunning: remnant ablation rates in 131-I scanned and non-scanned individuals. J Clin Endocrinol Metab 2001; 86:3507-3511.
31. Robbins R,Tuttle M, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001; 86:619-625.